Literature DB >> 18718121

Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.

Lauren Oleson1, Michael H Court.   

Abstract

Glucuronidation studies using microsomes and recombinant uridine diphosphoglucuronosyltransferases (UGTs) can be complicated by the presence of endogenous beta-glucuronidases, leading to underestimation of glucuronide formation rates. Saccharolactone is the most frequently used beta-glucuronidase inhibitor, although it is not clear whether this reagent should be added routinely to glucuronidation incubations. Here we have determined the effect of saccharolactone on eight different UGT probe activities using pooled human liver microsomes (pHLMs) and recombinant UGTs (rUGTs). Despite the use of buffered incubation solutions, it was necessary to adjust the pH of saccharolactone solutions to avoid effects (enhancement or inhibition) of lowered pH on UGT activity. Saccharolactone at concentrations ranging from 1 to 20 mM did not enhance any of the glucuronidation activities evaluated that could be considered consistent with inhibition of beta-glucuronidase. However, for most activities, higher saccharolactone concentrations resulted in a modest degree of inhibition. The greatest inhibitory effect was observed for glucuronidation of 5-hydroxytryptamine and estradiol by pHLMs, with a 35% decrease at 20 mM saccharolactone concentration. Endogenous beta-glucuronidase activities were also measured using various human tissue microsomes and rUGTs with estradiol-3-glucuronide and estradiol-17-glucuronide as substrates. Glucuronide hydrolysis was observed for pHLMs, lung microsomes and insect-cell expressed rUGTs, but not for kidney, intestinal or human embryonic kidney HEK293 microsomes. However, the extent of hydrolysis was relatively small, representing only 9-19% of the glucuronide formation rate measured in the same preparations. Consequently, these data do not support the routine inclusion of saccharolactone in glucuronidation incubations. If saccharolactone is used, concentrations should be titrated to achieve activity enhancement without inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718121      PMCID: PMC2697495          DOI: 10.1211/jpp.60.9.0009

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  28 in total

Review 1.  Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.

Authors:  Michael H Court
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  Validation of serotonin (5-hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6.

Authors:  Soundararajan Krishnaswamy; Su X Duan; Lisa L Von Moltke; David J Greenblatt; Michael H Court
Journal:  Drug Metab Dispos       Date:  2003-01       Impact factor: 3.922

3.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

Authors:  M B Fisher; K Campanale; B L Ackermann; M VandenBranden; S A Wrighton
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

4.  Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.

Authors:  Michael H Court; Su X Duan; Chantal Guillemette; Kim Journault; Soundararajan Krishnaswamy; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

5.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

Authors:  Daniel C Kemp; Peter W Fan; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

6.  High-performance liquid chromatographic assay for acetaminophen glucuronide in human liver microsomes.

Authors:  K M Alkharfy; R F Frye
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-04-05

7.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

8.  The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases.

Authors:  Matthew G Soars; Barbara J Ring; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

9.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.

Authors:  Michael H Court; Soundarajan Krishnaswamy; Qin Hao; Su X Duan; Christopher J Patten; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

Review 10.  Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

Authors:  John O Miners; Ross A McKinnon; Peter I Mackenzie
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

View more
  13 in total

1.  Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Authors:  Brandon T Gufford; Tyler N Graf; Noemi D Paguigan; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-08-27       Impact factor: 3.922

2.  Overestimation of flavonoid aglycones as a result of the ex vivo deconjugation of glucuronides by the tissue β-glucuronidase.

Authors:  Qing-Yi Lu; Lifeng Zhang; Guido Eibl; Vay Liang W Go
Journal:  J Pharm Biomed Anal       Date:  2013-10-05       Impact factor: 3.935

Review 3.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

4.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

5.  Hepatic Transport of 25-Hydroxyvitamin D3 Conjugates: A Mechanism of 25-Hydroxyvitamin D3 Delivery to the Intestinal Tract.

Authors:  Chunying Gao; Michael Z Liao; Lyrialle W Han; Kenneth E Thummel; Qingcheng Mao
Journal:  Drug Metab Dispos       Date:  2018-02-21       Impact factor: 3.922

6.  In vitro-in silico-based analysis of the dose-dependent in vivo oestrogenicity of the soy phytoestrogen genistein in humans.

Authors:  Rungnapa Boonpawa; Albertus Spenkelink; Ans Punt; Ivonne M C M Rietjens
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

7.  Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Authors:  Camilla Höglund; Nina Sneitz; Anna Radominska-Pandya; Liisa Laakonen; Moshe Finel
Journal:  Steroids       Date:  2011-08-09       Impact factor: 2.668

8.  Major glucuronide metabolites of testosterone are primarily transported by MRP2 and MRP3 in human liver, intestine and kidney.

Authors:  Cindy Yanfei Li; Abdul Basit; Anshul Gupta; Zsuzsanna Gáborik; Emese Kis; Bhagwat Prasad
Journal:  J Steroid Biochem Mol Biol       Date:  2019-04-05       Impact factor: 4.292

9.  Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice.

Authors:  Amanda LoGuidice; Bret D Wallace; Lauren Bendel; Matthew R Redinbo; Urs A Boelsterli
Journal:  J Pharmacol Exp Ther       Date:  2012-02-10       Impact factor: 4.030

10.  Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability.

Authors:  Zhican Wang; Timothy Wong; Takanori Hashizume; Leslie Z Dickmann; Michele Scian; Nicholas J Koszewski; Jesse P Goff; Ronald L Horst; Amarjit S Chaudhry; Erin G Schuetz; Kenneth E Thummel
Journal:  Endocrinology       Date:  2014-03-18       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.